Maternal Health Pandemic Response Act

Support for reproductive rights in the following legislation and government actions: H.R. 4104 / S. 2149, Health Equity and Access under the Law (HEAL) For Immigrant Families H.R. 4611 / S. 2377, Equal Access to Abortion Coverage in Health Insurance (EACH) Act H.R. 12 / S. 2150, Womens Health Protection Act (WHPA) H.R. 2029 / S. 951, Stop Comstock Act H.R. 5202 / S. 1598, BABIES Act H.R. 6394 / S. 1599, Midwives for MOMS Act of 2025 H.R. 8074 / S. 4195, Kira Johnson Act H.R. 8089 / S. 4186, Perinatal Workforce Act H.R. 8582 / S. 4436, Protecting Human Rights and Public Health in Foreign Assistance Act H.R. 8807 / S. 4550, Maternal Health Pandemic Response Act H.R. 9470 / S. 4920, SAFER Health Act of 2026 H.R. 4876, Reproductive Freedom for Veterans Act H.R. 9441, SAFE Training for OB-GYNs Act H.R. 211, Equal Access to Contraception for Veterans Act Offered as an amendment to H.R. 8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes. S. 3799, Healthy Start Reauthorization Act of 2026 S. 4574, MARCH for Military Servicemembers Act H.J.Res. 144 / S.J.Res. 103, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Veterans Affairs relating to "Reproductive Health Services". Advocating for the use of science and accurate data to support decision-making in government policy with respect to mifepristone Providing feedback about provisions impacting reproductive rights in the following legislation: H.R. 7973, Momnibus Act H.Res. 1277, Resolution on Human Rights H.Res. 1389, Expressing the sense of the House of Representatives that the monitoring and regulation of water systems not be weaponized for the purposes of surveilling, tracking, or detecting use of, stigmatizing, and further restricting access to medication abortion care. Opposing provisions impacting reproductive rights in the following legislation: H.R. 1, One Big Beautiful Bill Act, Section 71113 "Federal Payments to Prohibited Entities. Advocacy regarding the impact of Section 71113 and urging Congress not to reinstate or extend the one-year Medicaid funding restriction affecting Planned Parenthood and Maine Family Planning H.R. 8800, National Defense Authorization Act for Fiscal Year 2027 H.R. 8469, Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes. Opposing all provisions in the following legislation or administrative actions: Department of Veteran Affairs, VA 38 CFR Part 17 RIN 2900-AS31 H.R. 589, FACE Act Repeal Act of 2025 S. 4873, Promoting Human Flourishing in Foreign Assistance Act "Anti-Weaponization Fund that could benefit individuals convicted of violating the FACE Act.

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); H.R. 8651/S. _____, Advancing Safe Medications for Moms and Babies Act; Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of labor and delivery units in rural hospitals on patient access to care and maternal morbidity and mortality; abortion training in obstetrics and gynecology residency programs (general); Teaching Health Center Graduate Medication Education program (general); implementation of P.L. 119-21, One Big, Beautiful Bill Act; implementation of Sec. 6501 of P.L. 119-75, Preventing Maternal Deaths Reauthorization Act; Telemedicine (general); S. 380/H.R. 1254, Rural Obstetrics Readiness Act; S. 1834/H.R. 3762, Supporting Healthy Moms and Babies Act; H.R. 7973, Momnibus Act; H.R. 7830, WELLS Act; H.R.8159, Gynecologic Pain Management Study Act; H.R.8160, Premenstrual Dysphoric Disorder Awareness and Research Act; H.R. 9441, SAFE Training for OBGYNs Act; H.R. 9061, PREEMPT Act; H.Res. 1282, a resolution recognizing ACOGs 75th anniversary; H.R. 8358, Breast Cancer Research Stamp Reauthorization Act; S. Res. 710, a resolution recognizing Maternal Mental Health Day; H.R. 9090/S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act; H.Res. 1323, a resolution recognizing National Menstrual Health Awareness Month; H.R. 8500, Timely Access to Coverage Decisions Act; H.R. 7694, Gwenns Law; S. 4878, Reproductive Health Care Training Act; H.R. _____/S. _____, Right to IVF Act; S. 4494, America Cures Act; maternal mortality review committees (general); Patient-physician relationship (general); Obstetrician-gynecologist workforce (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Insurance coverage for infertility (general); Protections for in vitro fertilization (general); Vaccination (general); childhood vaccine recommendations (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); inclusion of pregnant and lactating women in clinical trials (general); pregnancy exposure registries (general); NIH/NICHD womens health research (general); access to fertility services and treatments (general); Restorative Reproductive Medicine (general); Advisory Committee on Immunization Practices (ACIP); COVID vaccine during pregnancy (general); S. 4550/H.R. 8807, Maternal Health Pandemic Response Act; United States Preventive Services Taskforce (general); hormone therapy for menopause symptoms (general); acetaminophen use during pregnancy (general); SSRI use during pregnancy (general); Pregnancy Risk Assessment Monitoring System (PRAMS); Maternal Mortality Review Information Application (MMRIA); FACE Act implementation; Nexplanon REMS; chaperones during sensitive procedures (general); FDA regulation of flavored e-cigarettes (general); ORR policies regarding pregnant minors (general); breast cancer risk assessment (general).

Client expense: $96,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Surface transportation and infrastructure policy affecting the electrical manufacturing industry, including the reauthorization of federal surface transportation programs; support for continued funding of the National Electric Vehicle Infrastructure (NEVI) Program; recognition of private-sector Buy America, Build America (BABA) compliance and certification resources, including NEMA's "Make It American" program; and legislation supporting domestic manufacturing and infrastructure investment, including the BUILD America 250 Act (H.R. 8807). Advocacy focused on policies to strengthen domestic manufacturing, supply chain resilience, transportation infrastructure investment, and deployment of electrical and transportation technologies.

Client expense: $650,000 · Firm income: Not reported

Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE